The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Open accessAbstract
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumours are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients. Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity. Preclinical experiments demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts. Toxicology studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clinical trials using a crystalline formulation of PLX4032 (ref. 5). In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following two weeks of treatment. This analysis revealed substantial inhibition of ERK phosphorylation, yet clinical evaluation did not show tumour regressions. At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumours of patients correlated with clinical response. Indeed, the Phase 1 clinical data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily. These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationPatterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Self-citationHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Cited by
Items 101–168 of 168
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Zhang, G., Frederick, D. T., Wu, L., Wei, Z., Krepler, C., Srinivasan, S., Chae, Y. C., Xu, X., Choi, H., Dimwamwa, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82661 · Cited by 286
Self-citationERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?
Buscà, R., Pouysségur, J., & Lenormand, P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00053 · Cited by 284
Parmenter, T. J., Kleinschmidt, M., Kinross, K. M., Bond, S. T., Li, J., Kaadige, M. R., Rao, A., Sheppard, K. E., Hugo, W., Pupo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0440 · Cited by 283
Self-citationKakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
Flockhart, R. J., Webster, D. E., Qu, K., Mascarenhas, N., Kovalski, J., Kretz, M., & Khavari, P. A. (2012) · Genome Research · doi:10.1101/gr.140061.112 · Cited by 277
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Codon-specific translation reprogramming promotes resistance to targeted therapy
Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271
BRAF targeted therapy changes the treatment paradigm in melanoma
Ribas, A., & Flaherty, K. T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.69 · Cited by 271
Self-citationProtein X-ray Crystallography and Drug Discovery
Maveyraud, L., & Mourey, L. (2020) · Molecules · doi:10.3390/molecules25051030 · Cited by 269
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
Self-citationRetractedAdvances in targeting cell surface signalling molecules for immune modulation
Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 267
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Pathogenesis of NUT Midline Carcinoma
French, C. A. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132438 · Cited by 264
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.18 · Cited by 264
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
Verissimo, C. S., Overmeer, R. M., Ponsioen, B., Drost, J., Mertens, S., Verlaan-Klink, I., Gerwen, B. V., van der Ven, M., Wetering, M. V. D., Egan, D. A., et al. (2016) · eLife · doi:10.7554/elife.18489 · Cited by 263
New Therapies for Advanced Thyroid Cancer
Laha, D., Nilubol, N., & Boufraqech, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00082 · Cited by 261
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
Elucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
“This finding is consistent with the observation that induction of tumor regression by PLX4032 requires almost complete suppression of ERK signaling (36).”
ResultSelf-citationHaling, J. R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W., Phung, W., Bravo, B. J., Giannetti, A. M., Peck, A., Masselot, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.007 · Cited by 252
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
Ahmed, T. A., Adamopoulos, C., Karoulia, Z., Wu, X., Sachidanandam, R., Aaronson, S. A., & Poulikakos, P. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.013 · Cited by 214
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216
“Vemurafenib (RG7204, PLX4032; RO5185426) is a potent and selective small molecule inhibitor of BRAF (15) that has been approved by the Food and Drug Administration for the treatment of latestage (metastatic) or unresectable melanoma in patients whose tumors express BRAF.”
Self-citationDevelopment of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203
Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.-Q., Buchanan, S., Henry, J. R., Starling, J. J., & Peng, S.-B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377218 · Cited by 200
Targeting Protein-Protein Interaction by Small Molecules
Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195
ERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
Identifying drug targets in tissues and whole blood with thermal-shift profiling
Perrin, J., Werner, T., Kurzawa, N., Rutkowska, A., Childs, D. D., Kalxdorf, M., Poeckel, D., Stonehouse, E., Strohmer, K., Heller, B., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0388-4 · Cited by 178
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
Natural polyphenols in cancer therapy
Asensi, M., Ortega, A., Mena, S., Feddi, F., & Estrela, J. M. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.631268 · Cited by 174
Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171
Self-citationAdvances in the preclinical testing of cancer therapeutic hypotheses
Caponigro, G., & Sellers, W. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3385 · Cited by 165
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
“Most importantly, both BRAF inhibitors are associated with the occurrence of skin tumours.(115,131) The most common reported skin cancer associated with BRAF inhibitors is squamous cell carcinoma.”
BackgroundRamsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143
Self-citationMutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Self-citationVella, L. J., Pasam, A., Dimopoulos, N., Andrews, M., Knights, A., Puaux, A.-L., Louahed, J., Chen, W., Woods, K., & Cebon, J. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0181 · Cited by 139
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
Self-citationBRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“However, while these RAF inhibitors demonstrated in vitro potency against all three RAF isoforms in biochemical assays 48,50 , they inhibit MEK and ERK activation only in cancer cells with BRAF V600 mutations 51 (Fig.”
Adolescent and young adult patients with cancer: a milieu of unique features
Sender, L., & Zabokrtsky, K. B. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.92 · Cited by 130
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119
A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*
Stuart, S. A., Houel, S., Lee, T., Wang, N., Old, W. M., & Ahn, N. G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047233 · Cited by 116
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
“…activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et al, 2012; Sosman et al, 2012).”
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Vin, H., Ojeda, S. S., Ching, G., Leung, M. L., Chitsazzadeh, V., Dwyer, D. W., Adelmann, C. H., Restrepo, M., Richards, K. N., Stewart, L. R., et al. (2013) · eLife · doi:10.7554/elife.00969 · Cited by 84
Self-citationDetermining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Klomp, J. E., Diehl, J. N., Klomp, J. A., Edwards, A. C., Yang, R., Morales, A. J., Taylor, K. E., Drizyte-Miller, K., Bryant, K. L., Schaefer, A., et al. (2024) · Science · doi:10.1126/science.adk0850 · Cited by 83
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73
“In the clinical setting, >90% ERK inhibition is required for responses in melanoma patients (36).”
Protein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
Ferguson, J., Arozarena, I., Ehrhardt, M., & Wellbrock, C. (2013) · Oncogene · doi:10.1038/onc.2012.25 · Cited by 68
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure
Zwirner, S., Abu Rmilah, A. A., Klotz, S., Pfaffenroth, B., Kloevekorn, P., Moschopoulou, A. A., Schuette, S., Haag, M., Selig, R., Li, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.023 · Cited by 65
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer
Blagden, S. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00149 · Cited by 66
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Yang, G., Yan, Y., Ma, Y., & Yang, Y. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22654 · Cited by 54
Martin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
Kholodenko, B. N. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.014 · Cited by 49
Giricz, O., Mo, Y., Dahlman, K. B., Cotto-Rios, X. M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D. B., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120422 · Cited by 40
Self-citationA novel MCF-10A line allowing conditional oncogene expression in 3D culture
Herr, R., Wöhrle, F. U., Danke, C., Berens, C., & Brummer, T. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-17 · Cited by 37
An, R., Merrill, D., Avramova, L., Sturgis, J., Tsiper, M., Robinson, J. P., Turek, J., & Nolte, D. D. (2014) · SLAS Discovery · doi:10.1177/1087057113516674 · Cited by 35
Zhang, X., Birtwistle, M., & Gallo, J. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.65 · Cited by 33
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
Hartsough, E. J., Kugel, C. H., Vido, M. J., Berger, A. C., Purwin, T. J., Goldberg, A., Davies, M. A., Schiewer, M. J., Knudsen, K. E., Bollag, G., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0705 · Cited by 27
Self-citationInducing Oncoprotein Degradation to Improve Targeted Cancer Therapy
Ray, D., Cuneo, K. C., Rehemtulla, A., Lawrence, T. S., & Nyati, M. K. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.008 · Cited by 22
“Vemurafenib (Zelboraf, Daiichi Sankyo) is a serine/threonine kinase inhibitor that is Food and Drug Administration (FDA) approved for patients with metastatic BRAF mutant melanoma [3].”
BackgroundBRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy
Yaeger, R., & Saltz, L. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0148 · Cited by 18
BRAFV600E dictates cell survival via c-Myc-dependent induction of Skp2 in human melanoma
Feng, L., Li, J., Bu, X., Zuo, Y., Shen, L., & Qu, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.085 · Cited by 8
Metadata
- Authors
- Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., Burton, E. A., Wong, B., Tsang, G., West, B. L., Powell, B., Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K. Y. J., Artis, D. R., Schlessinger, J., Su, F., Higgins, B., Iyer, R., D’Andrea, K., Koehler, A., Stumm, M., Lin, P. S., Lee, R. J., Grippo, J., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., Chapman, P. B., Flaherty, K. T., Xu, X., Nathanson, K. L., & Nolop, K.
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7315
- Pages
- 596-599
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971947883
- Cited by
- 1,831
- References
- 27
- FWCI
- 72.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.